Abstract

Introduction and objectivesTo assess the management and implementation of the European Society of Cardiology Guidelines on atrial fibrillation (AF), in a contemporary cohort of AF patients. MethodsREGUEIFA is a prospective, multicenter and observational study of patients diagnosed with primary or secondary AF, dwelling in the region of Galicia and evaluated by cardiologists. ResultsOne thousand and seven patients have been recruited. Mean age was 67±11 years and 32% were women. Fifty percent of patients have underlying cardiovascular disease. Amiodarone was the antiarrhythmic drug more often used (24,5%). The thromboembolic risk assessed by CHA2DS2-VASc score was 2.3±1.5 and the bleeding risk assessed by HASBLED score was 0.7±0.7. Oral anticoagulant therapy (OAC) was prescribed in 90.1%. CHA2DS2-VASc score, hypertension and AF ablation were independent predictor factors of OAC and paroxysmal AF was associated with no anticoagulation. Age and renal insufficiency, were independent predictor factors of vitamin K antagonists prescription whereas electrical cardioversion and AF ablation were independent predictor factors of direct oral anticoagulation therapy prescription. ConclusionsREGUEIFA registry provides contemporary information on AF management by cardiologists. Prescription of OAC was 91,1%. Independent predictor factors associated with OAC and direct oral anticoagulation prescription were described.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.